Literature DB >> 16644905

Trends in the treatment of breast cancer in Southeast England following the introduction of national guidelines.

Daniela Tataru1, David Robinson, Henrik Møller, Elizabeth Davies.   

Abstract

There is little published evidence on trends in the treatment of breast cancer in England following the publication of the Calman-Hine report in 1995. Reliable national data are available for women with screen-detected breast cancer, but data on women presenting symptomatically have been difficult to collect. Using data from both a clinical audit database and a population-based cancer register, we show that between 1996 and 2003 the rates of mastectomy and chemotherapy treatment for women with breast cancer in Southeast England have increased marginally, whereas there has been a steady decline in the use of hormone therapy and radiotherapy recorded within 6 months of diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644905     DOI: 10.1093/pubmed/fdl011

Source DB:  PubMed          Journal:  J Public Health (Oxf)        ISSN: 1741-3842            Impact factor:   2.341


  4 in total

1.  Guideline-compatible treatment of breast cancer patients: the status quo in schleswig-holstein.

Authors:  Annika Waldmann; Ron Pritzkuleit; Heiner Raspe; Alexander Katalinic
Journal:  Dtsch Arztebl Int       Date:  2008-05-02       Impact factor: 5.594

Review 2.  Strategies for reducing regional variation in the use of surgery: a systematic review.

Authors:  Bradley N Reames; Sarah P Shubeck; John D Birkmeyer
Journal:  Ann Surg       Date:  2014-04       Impact factor: 12.969

3.  Predictors of early death in female patients with breast cancer in the UK: a cohort study.

Authors:  Ceilidh Stapelkamp; Lars Holmberg; Daniela Tataru; Henrik Møller; David Robinson
Journal:  BMJ Open       Date:  2011-11-28       Impact factor: 2.692

4.  Breast cancer in young women: poor survival despite intensive treatment.

Authors:  Hanna Fredholm; Sonja Eaker; Jan Frisell; Lars Holmberg; Irma Fredriksson; Henrik Lindman
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.